Beta 2 Glycoprotein 1 Panel IgG, IgM & IgA

The Beta 2 Glycoprotein 1 IgG Serum test detects the presence of immunoglobulin G (IgG) antibodies against Beta 2 Glycoprotein 1, a protein that plays a crucial role in regulating blood clotting. IgG indicates a chronic or ongoing immune response against β2GPI, which is often associated with an increased risk of blood clotting disorders such as those seen in APS. Elevated levels of these antibodies suggest a higher risk for thrombotic events, such as deep vein thrombosis (DVT), stroke, or miscarriage, particularly when coupled with other clinical factors. By detecting IgG antibodies, this test aids in diagnosing APS and determining the need for medical interventions to manage clotting risk, including anticoagulant therapy or closer monitoring in pregnancy.

The Beta 2 Glycoprotein 1 IgM, Serum test checks for the presence of immunoglobulin M (IgM) antibodies against Beta 2 Glycoprotein 1, a protein that helps regulate blood clotting. IgM antibodies are usually the first type of antibody the body makes in response to new infections or autoimmune issues. Elevated IgM (Immunoglobulin M) levels can indicate an ongoing or recent infection, or they can suggest an autoimmune response. In the context of pregnancy, high IgM levels might be associated with certain conditions like antiphospholipid syndrome or other immune-related issues that could affect pregnancy outcomes. When doctors notice high IgM levels, particularly in pregnant women, it can guide decisions like monitoring the pregnancy more closely for signs of complications, including preterm labor or fetal growth restrictions, considering blood thinners (like heparin or aspirin), especially if the patient is at risk of clotting disorders, which are associated with higher IgM levels in some cases and  checking for infections (e.g., TORCH infections) that could pose risks to the baby.